AbbVie sees 80% discounting
Discounts due to biosimilar competition have risen as high as 80% in Europe, according to AbbVie chairman and chief executive officer Richard Gonzalez. Noting that Remicade (infliximab) and Enbrel (etanercept) were the “analogs” that AbbVie had used to plan for the onset of biosimilar competition to its Humira (adalimumab) brand in Europe, he observed that discounting on infliximab and etanercept “ranges from as low as 10% to as high as around 80%”, with “the higher discounting seen in the Nordic tender countries”.
You may also be interested in...
Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.
Mylan’s Hulio has become the sixth biosimilar version of Humira to be approved by the US FDA. However, all of these adalimumab biosimilars face a wait until 2023 before they can enter the market.
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.